Hikma Shares Surge 10% on H1 Profit Beat

Key Facts

In a move reflecting the resilience of the healthcare sector amid economic shifts, Hikma Pharmaceuticals shares saw a significant rally. The company's stock jumped 10% to reach 1,721p following the announcement of strong first-half 2026 financial results that exceeded market expectations. According to reports, the surge was triggered by a substantial profit beat, leading analysts at Peel Hunt and Stifel to maintain their 'buy' recommendations for the stock.

Financial data showed that the Branded division's revenue grew 15% to $502 million, while its operating profit rose 23%. The group's core operating profit reached $405 million, approximately 11% above the $364 million analyst consensus. Despite this strong performance, Hikma left its full-year guidance unchanged, targeting revenue growth of 2% to 4% and core operating profit between $720 million and $770 million.

Technically, the share price is approaching Stifel's target of 1,700p, while Peel Hunt maintains a higher target of 1,880p. As real-time price data is currently unavailable, investors are monitoring the sustainability of these levels. Traders in the UK market are also keeping an eye on broader monetary policy impacts, following the recent decision to hold interest rates at 3.75% at the end of July.